Rethinking time to diagnosis in patients with hip fracture: the role of SGLT2 inhibitors
Published
October 26, 2023
Paper ID
PAP-000145
Status
Published
DOI
10.65712/tmj.test000403
Advance Services
Abstract
Background: The cost of time to diagnosis to health systems is substantial. Methods: Eligible participants were patients with hip fracture. Results: time to diagnosis occurred in 20% of the intervention group versus 24% of controls. Effects were consistent across prespecified subgroups. Conclusion: Residual confounding cannot be excluded.
Introduction
Guidelines make only a weak recommendation on SGLT2 inhibitors. The cost of time to diagnosis to health systems is substantial.
The cost of time to diagnosis to health systems is substantial. Earlier studies of SGLT2 inhibitors were small or single-centre. time to diagnosis remains a leading cause of avoidable harm among patients with hip fracture.
Guidelines make only a weak recommendation on SGLT2 inhibitors. Earlier studies of SGLT2 inhibitors were small or single-centre.
Materials and Methods
Eligible participants were patients with hip fracture. The primary outcome was time to diagnosis, assessed blind to allocation.
Missing data were handled with multiple imputation. Eligible participants were patients with hip fracture. Analyses were adjusted for age, sex and baseline severity.
The primary outcome was time to diagnosis, assessed blind to allocation.
The primary outcome was time to diagnosis, assessed blind to allocation. Missing data were handled with multiple imputation. We conducted a retrospective cohort study across 14 centres between 2019 and 2023.
Results
Effects were consistent across prespecified subgroups. 1994 participants were included (median age 44 years).
Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Age ≥ 65 | 782 | 104 | 11.0 | 0.57 | 0.46–1.3 |
| Centre B | 375 | 32 | 16.7 | 0.54 | 0.42–1.15 |
| Centre B | 481 | 26 | 21.7 | 0.71 | 0.22–1.39 |
| Control | 357 | 105 | 33.9 | 0.56 | 0.56–1.3 |
| Centre A | 848 | 44 | 12.7 | 0.72 | 0.41–1.6 |
Values are n (%) unless stated otherwise.

Shown for patients with hip fracture; error bars are 95% confidence intervals.

Shown for patients with hip fracture; error bars are 95% confidence intervals.
The adjusted odds ratio was 0.85 (95% CI 0.41 to 0.62). Effects were consistent across prespecified subgroups.
1639 participants were included (median age 45 years). Effects were consistent across prespecified subgroups.
Discussion
Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.
Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols.
Future work should test SGLT2 inhibitors in a pragmatic multicentre trial. These findings suggest that SGLT2 inhibitors is associated with better time to diagnosis in patients with hip fracture. Strengths include the sample size and blinded outcome assessment.
Conclusions
SGLT2 inhibitors is a reasonable option for patients with hip fracture to improve time to diagnosis.
References
1. Tanaka L, Dubois M, et al. An enhanced recovery pathway and post-operative delirium. JAMA. 2022;275(8):480-997.
2. Lindqvist N, Ahmed R, et al. Early mobilisation and emergency department revisits. Ann Intern Med. 2010;38(9):587-1073.
3. Mensah Y, Nasser H, et al. Point-of-care ultrasound and health-related quality of life. Pediatrics. 2013;395(3):57-1617.
4. Zhang E, Lindqvist X, et al. Delayed cord clamping and ventilator-free days. JAMA. 2010;130(3):717-1062.
5. Volkov Z, Zhang U, et al. Early enteral nutrition and emergency department revisits. JAMA. 2011;205(11):717-1651.
Appendices
The statistical analysis plan is in the online supplement.